DISCLAIMER: This page is intended for members of the general public in Portugal only.

The information provided on this site is intended for general information and education for Portugal-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.

Information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373)

NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted a conditional marketing authorisation for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older, and as a booster dose approximately 6 months after the second dose in individuals 18 years of age and older.

Important information

For more information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted), download the Package Leaflet.

Report an Adverse Event (AE)

If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Package Leaflet.

Either you or your healthcare professional can report any suspected adverse reactions via the national reporting system of Portugal.

Sítio da internet: www.infarmed.pt/web/infarmed/submissaoram
(preferencialmente)
ou através dos seguintes contactos:
Direção de Gestão do Risco de Medicamentos
Parque da Saúde de Lisboa, Av. Brasil 53
1749-004 Lisboa

Tel: +351 21 798 73 73
Linha do Medicamento: 800222444 (gratuita)
e-mail: [email protected]

Contact Us

Tel: +351 21 020 6287
09:00 - 17:00
Monday - Friday